Nov 16, 2023 | Press Releases
CULVER CITY, Calif., November 16, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler Healthcare Conference, which is taking place in New York City,...
Nov 7, 2023 | Press Releases
Findings from NCI-led study suggest that Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors M-ceNK may provide an additional line of therapy in other...
Oct 26, 2023 | Press Releases
BLA for N-803 plus BCG in high-risk non-muscle-invasive bladder cancer (NMIBC) was resubmitted to the Agency on October 23, 2023 A new PDUFA date of April 23, 2024 has been communicated by the Agency CULVER CITY, Calif., October 26, 2023 — ImmunityBio, Inc. (NASDAQ:...
Oct 23, 2023 | Press Releases
Provides updated data on prolonged duration of complete response in BCG-Unresponsive and BCG-Naïve NMIBC patients Following the Type A Meeting with the FDA, ImmunityBio has completed the BLA resubmission addressing the issues in the Complete Response Letter. As part...
Sep 11, 2023 | Press Releases
Financing improves the company’s balance sheet and provides $200 million of capital, as follows: Exchange of $270 million of debt held by Nant Entities into ImmunityBio equity resulting in deleveraging of the Company’s balance sheet $200 million of a new 3-year term...
Aug 3, 2023 | Press Releases
Veteran manufacturing and supply chain expert to oversee global manufacturing and QA CULVER CITY, Calif., August 3, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly...